Navigation Links
PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS
Date:5/20/2009

nebulizer, such as the customized small droplet generating eFlow electronic nebulizer," stated Dr. Alexander Moeller, head of the Research Division, Respiratory Medicine at the University Children's Hospital Zurich, Switzerland.

Previous DSCG therapies were only moderately effective, since the interaction of the very hygroscopic properties of DSCG with the drug delivery system were not understood.

"We believe our novel, higher concentrated, low volume DSCG formulation delivered via an optimized Investigational eFlow Nebulizer System opens new treatment avenues and perspectives for patients and physicians. This expectation is further supported by newly published data on a potential antiviral efficacy of DSCG that may be particularly important in the treatment of pediatric asthma," added Dr. Manfred Keller, chief scientific officer and executive vice president of PARI Pharma.

At ATS, PARI Pharma also presented in-vitro data comparing IsoCrom (1%) with a novel, higher concentrated (6%), low volume DSCG formulation that requires significantly less nebulization time than IsoCrom. The results of this in-vitro study using 45mg/0.75ml may allow the option for twice-daily administration in less than 2.5 minutes.

IsoCrom & ICS Comparative Study Results

Data from a randomized, open-label, Phase II, six-month study comparing efficacy and safety of an IsoCrom solution versus inhaled steroids was presented by researchers from the pediatric department of the University Hospital Zurich, Switzerland. Twenty eight children (11.9 +/- 2.8 years) with stable atopic asthma were randomized to inhale either IsoCrom, delivered at a dose of 60 mg per day administered in three inhalations of 2ml using a customized small droplet Investigational eFlow Nebulizer System, or inhaled corticosteroids (ICS) without dose adjustments administered in two inhalations using a metered dose Inhaler (MDI) via a holding
'/>"/>

SOURCE PARI Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ePharmaSolutions Clinical Trial Investigator Portal Wins Bio-IT World 2009 Best Practice Award
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
4. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
5. Pharmasset Reports Fiscal Year End 2008 Financial Results
6. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
7. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
8. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
9. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
10. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... DIEGO, Calif. and RESEARCH TRIANGLE PARK, N.C. ... (Nasdaq: OREX ), a biopharmaceutical company focused on ... a global provider of drug development and manufacturing services, ... Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as ...
... Inc. (Headquarters: Woodcliff Lake, New Jersey , Chairman and CEO: Hajime Shimizu , "Eisai") today announces ... (Headquarters: Baltimore, Maryland , Director: John Griffin , M.D., "BSI") related to Eisai,s GCPII (glutamate carboxypeptidase ... ... , ...
Cached Medicine Technology:Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) 2Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) 3Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) 4Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) 5Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute 2Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute 3
(Date:4/17/2014)... 17, 2014U.S. military personnel who served in Iraq ... traumatic brain injury (TBI) were compared to military ... medical reasons. Differences in measures of overall disability, ... after injury are reported in an article in ... from Mary Ann Liebert, Inc., publishers. The article ...
(Date:4/17/2014)... estimated that as many as 10 million older Americans ... loneliness and isolation. , However, new research a ... older Americans for six years found that Internet ... depression by more than 30 percent. , "That,s a ... University professor of telecommunication, information studies and media who ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
(Date:4/17/2014)... School of Medicine (BUSM) have discovered that the ... experimental model. The findings, reported in the ... may lead to more effective treatments for alcoholism. ... the leading causes of illness and death in ... by limiting the productivity of workers and necessitating ...
(Date:4/17/2014)... (SACRAMENTO, Calif.) An international team led by researchers ... protein complex, which plays a key role in cell ... process. This is the first time the complex has ... could make cyclin B1/Cdk1 an excellent target to control ... medicine. The research was published online today in the ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... Earns 510(k) Clearance for AutoLITT(TM)KALAMAZOO, Mich., and WINNIPEG, Manitoba, ... investigational use at both The Cleveland Clinic and University ... brain tumor patients and has earned clearance from the ... The first applications of the technology are expected ...
... for all health data processing and transactionsPARSIPPANY, ... healthcare EDI company that processes insurance transactions ... has achieved full accreditation with the Healthcare ... Healthcare Network Accreditation Commission (EHNAC). EHNAC,s HNAP ...
... nonprofit leader in ending homelessness at its roots, today ... Council, a group of some of the nation,s leading ... Council members, many of whom are veterans themselves, will ... experience to enable Jericho to serve veterans from all ...
... IBM (NYSE: IBM ) today announced that ... Excellence located in La Gaude, France. (Logo: ... global healthcare capability, the Centre of Excellence will help ... sciences solutions that improve care delivery, predict and prevent ...
... Medical Center-University surveyCHARLOTTE, N.C., May 13 Dr. ... a top score for plastic surgery in the ... a tremendous honor for Dr. Capizzi and his ... coordinates the program and selects the honorees. "The ...
... In U.S., 40 percent of new moms aren,t married, CDC ... The number of unmarried women having children has risen sharply ... U.S. health officials. , In the United States, 40 percent ... these are to women in their 20s, not teenagers, according ...
Cached Medicine News:Health News:Treating Untreatable Brain Tumors: FDA Approves New Laser Surgery 2Health News:MD On-Line, Inc. Receives EHNAC Healthcare Network Accreditation 2Health News:MD On-Line, Inc. Receives EHNAC Healthcare Network Accreditation 3Health News:Jericho Project Creates Veterans Advisory Council 2Health News:Jericho Project Creates Veterans Advisory Council 3Health News:Jericho Project Creates Veterans Advisory Council 4Health News:IBM Establishes Global Healthcare Centre of Excellence in La Gaude, France 2Health News:IBM Establishes Global Healthcare Centre of Excellence in La Gaude, France 3Health News:Dr. Peter J. Capizzi of Stillwater Plastic Surgery Honored in Patient Satisfaction Survey 2Health News:More Single Women Are Having Babies 2Health News:More Single Women Are Having Babies 3Health News:More Single Women Are Having Babies 4
... Retractor System represents the most widely ... Its wide array of retraction components ... versatile system for multi-directional exposure of ... are available for specific procedures: IMA ...
Rainbow technology combines the latest in system theory, adaptive signal processing and a revolutionary sensor that employs eight wavelengths of light to collect and analyze an extraordinarily rich s...
... real-time PCR analysis of gene expression ... LightCycler 480 System combines amazing speed ... the needs of a broad range ... including array validation, gene-knockdown studies, and ...
... PyGON now offers a very unique product series, ... alarm dialing for refrigerators and freezers. This is ... only a phone line. With our VM500 solution ... to 128 points over one phone line. The ...
Medicine Products: